Q-omics provides the consensus-scored GDF15 profile across patient tissues and cancer cell-line models. GDF15 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, GDF15 is differentially expressed in 14, with the highest sampling consensus in COAD. Additionally, GDF15 RNA expression shows 15,645 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight UVM, COAD, and TGCT as cancer lineages where GDF15 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for GDF15 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes GDF15 survival associations across molecular data types. GDF15 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (3) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible GDF15 RNA expression–survival associations across cancer types. High GDF15 expression shows unfavorable associations in UVM, MESO, LGG and UCS, but favorable associations in KIRC and UCEC. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for GDF15 RNA expression.
This table summarizes GDF15 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 4. The strongest signals are observed in KIRC for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for GDF15. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. GDF15 shows lower tumor expression in KIRC and higher tumor expression in COAD, THCA, STAD, BRCA and LIHC. The COAD box plot shows higher GDF15 RNA expression in tumor versus normal tissue (log2 FC = +4.353, t-test p < 0.001).
This table shows molecular features associated with GDF15 in patient tissues and cancer cell lines. In patient samples, GDF15 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, GDF15 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUAD and BONE.
